Autoantibodies to factor VIII with catalytic activity.

[1]  D. Cooper,et al.  The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene , 1990, Human Genetics.

[2]  S. Kaveri,et al.  The prevalence of proteolytic antibodies against factor VIII in hemophilia A. , 2002, The New England journal of medicine.

[3]  P. Thiagarajan,et al.  Monoclonal antibody light chain with prothrombinase activity. , 2000, Biochemistry.

[4]  S. Kaveri,et al.  Catalytic activity of antibodies against factor VIII in patients with hemophilia A , 1999, Nature Medicine.

[5]  J. Vermylen,et al.  Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes , 1999, Thrombosis and Haemostasis.

[6]  M. Shima,et al.  Some human inhibitor antibodies interfere with factor VIII binding to factor IX. , 1998, Blood.

[7]  S. Hinrichs,et al.  Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. , 1997, Journal of immunology.

[8]  G. E. Gilbert,et al.  Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition* , 1996, The Journal of Biological Chemistry.

[9]  D. Semenov,et al.  Phosphorylation of different human milk proteins by human catalytic secretory immunoglobulin A , 1996, Biochemistry and molecular biology international.

[10]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[11]  F. Stevens,et al.  Natural Catalytic Antibodies: Peptide-hydrolyzing Activities of Bence Jones Proteins and VL Fragment (*) , 1995, The Journal of Biological Chemistry.

[12]  M. Kazatchkine,et al.  Catalytic Activity of Anti‐Thyroglobulin Antibodies a , 1995, Journal of immunology.

[13]  I. Smirnov,et al.  Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. R. Thomas.  Hapten design for the generation of catalytic antibodies , 1994, Applied biochemistry and biotechnology.

[15]  M. Shima,et al.  A role for the C2 domain of factor VIII in binding to von Willebrand factor. , 1994, The Journal of biological chemistry.

[16]  A. Gabibov,et al.  DNA‐specific antiidiotypic antibodies in the sera of patients with autoimmune diseases , 1992, FEBS letters.

[17]  I. Smirnov,et al.  DNA hydrolyzing autoantibodies. , 1992, Science.

[18]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[19]  S. Eklund,et al.  Vasoactive intestinal peptide hydrolysis by antibody light chains. , 1991, The Journal of biological chemistry.

[20]  F. Hamel,et al.  Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. , 1991, The Journal of biological chemistry.

[21]  R. Massey,et al.  Site specificity of a catalytic vasoactive intestinal peptide antibody. An inhibitory vasoactive intestinal peptide subsequence distant from the scissile peptide bond. , 1990, The Journal of biological chemistry.

[22]  R. Massey,et al.  Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. , 1989 .

[23]  L. Hoyer,et al.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. , 1989, The Journal of clinical investigation.

[24]  J. Ware,et al.  Identification of a F.VIII epitope recognized by a human hemophilic inhibitor. , 1989, Blood.

[25]  R. Houghten,et al.  Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. , 1988, The Journal of biological chemistry.

[26]  R. Houghten,et al.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. , 1988, The Journal of clinical investigation.

[27]  S. Shapiro.  The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8. , 1967, The Journal of clinical investigation.

[28]  L. Pauling,et al.  Nature of Forces between Large Molecules of Biological Interest , 1948, Nature.